Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04107285 · ClinicalTrials.gov registry record
Looking at Cognitive and Brain Changes in People With Lymphoma Receiving CAR-T Therapy
A clinical trial of Lymphoma Receiving CAR-T Therapy, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- 120
- Enrollment target
- 1
- Study location
NCT04107285: Recruiting study of Lymphoma Receiving CAR-T Therapy, sponsored by Memorial Sloan Kettering Cancer Center.
NCT04107285 is a study of Lymphoma Receiving CAR-T Therapy that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 120 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04107285, a study of Lymphoma Receiving CAR-T Therapy, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to learn about possible changes in cognitive (mental) abilities, such as memory skills and concentration, and in brain anatomy (structure) and function, in people with lymphoma receiving CAR-T therapy.
Primary Outcome
correlations of neurocognitive scores with the FACIT-FS (fatigue) scale score The Functional Assessment of Chronic Illness Therapy-Fatigue Subscale, Version 4 (FACITFS V-4 56, is a 13-item questionnaire designed to assess symptoms and concerns specific to the QOL of patients with fatigue \[66\]. The questionnaire asks respondents to indicate the extent to which each item applied to them over "the past 7 days" using a 5-point Likert-type response format ranging from "0 - Not at all" to "4 - Very
Conditions Studied
Interventions
- BEHAVIORAL neurocognitive evaluations
- DIAGNOSTIC_TEST brain MRIs
- OTHER Blood samples
Study Locations (1)
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2019-09-25 |
| Est. Completion | 2026-09 |
What NCT04107285 shows while recruiting
NCT04107285 is an observational study that tracks outcomes without assigning an intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap.
The record links to 1 condition, with Lymphoma Receiving CAR-T Therapy appearing as the primary indexed condition, and to 3 interventions - of which neurocognitive evaluations is the first listed.
NCT04107285 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT04107285 about?
NCT04107285 is a clinical study titled "Looking at Cognitive and Brain Changes in People With Lymphoma Receiving CAR-T Therapy". The purpose of this study is to learn about possible changes in cognitive (mental) abilities, such as memory skills and concentration, and in brain anatomy (structure) and function, in people with lymphoma receiving CAR-T therapy.
What is the current status of trial NCT04107285?
This trial is currently recruiting. The enrollment target is 120 participants. The study started on 2019-09-25. Estimated completion is 2026-09.
What conditions does trial NCT04107285 study?
This clinical trial studies the following conditions: Lymphoma Receiving CAR-T Therapy.
What interventions are being tested in trial NCT04107285?
The interventions under investigation include: neurocognitive evaluations (BEHAVIORAL), brain MRIs (DIAGNOSTIC_TEST), Blood samples (OTHER).
Who is sponsoring clinical trial NCT04107285?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04107285 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI